Andrés Ferreri

Unità Linfomi - Dipartimento Oncoematologia -Istituto Scientifico San Raffaele - Milano · Ospedale San Raffaele, Milan, Italy

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Andrés Ferreri as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:30 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT04915248 · Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Fondazione Italiana Linfomi - ETS · recruiting · Plasmablastic Lymphoma · principal investigator
Ph2
NCT01820910 · Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment
International Extranodal Lymphoma Study Group (IELSG) · completed · Marginal Zone Lymphoma of Ocular Adnexal · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:30 UTC. The ranking covers the 200 most relevant of 73 PubMed records, and a shared surname and initials can bring in a namesake. All 73 on PubMed